Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Oncopeptides, Audiocast with teleconference, Q3'24

By Inderes11/7/2024, 9:00 AM
Oncopeptides

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Sofia Heigis
00:00 - 02:44

Hi everyone, and welcome to this presentation of our report for the third quarter of 2024. This is our standard disclaimer. As always, I have Henrik Bergentoft with me to give a financial update. Before that, I will go over some key points for the third quarter. I will then come back with an update on our European commercialization and provide a deep dive into our three key markets in Europe: Germany, including Austria, Spain, and Italy. Starting off with some key highlights, the revenue in Q3 was 8.5 million, a slight increase versus Q2 and without the milestone payment from SCBIO Inc. for South Korea. European sales in the third quarter are slightly lower than in the second quarter, which in turn showed a 60% increase over Q1. We do see a strong start in Spain, where during this quarter we have broad and regional access. Year to date, we have unlocked 80% of the regions, which we are pleased with. The speed at which we are moving is due to a high unmet need for Pepaxti and a result of positive clinical experiences pre-launch among investigators and top key opinion leaders. This means that the strong initial interest we saw in Spain in the second quarter has started to transform into sales. This is, however, offset by a soft German market where we are seeing slower than expected growth. The slightly lower sales are due to a change in ordering patterns in Greece by the authorities, meaning very low sales in this country during Q3. Hence, Q3 as a whole is based on this dynamic and mixed quarter, illustrating volatility in an early stage launch on the market. Reactions. This morning. We do appreciate our high expectations and rest assured, we are fully committed to continuing to grow sales to reach our profitability goal in 2026. Following this slower than expected sales development in Q3, Oncopeptides is acting by implementing an even stronger focus on our three largest markets: Germany, Spain, and Italy, while reducing our cost base elsewhere. We are doing this without impairing our ability to market and sell Pepaxti in the countries where we see the greatest near-term potential. I will talk more about our key markets and the strategy we have. But first, I will hand over to Henrik for a detailed look at the finances.

Henrik Bergentoft
02:46 - 06:16

So, thank you, Sofia. Starting off with an overview of the profit and loss statement for the fourth quarter and the nine-month period compared to the same period last year. Firstly, I want to highlight with regards to sales that last year includes a reversal of return reserve in the US, where underlying sales for the nine month period in 2023 amounted to $5.6 billion, compared now to the $21.7 million for the nine month period of 2024. Secondly, last year's operating expenses were positively affected by a refund of $43 million related to the closure of a clinical study. Meaning that underlying expenses for the nine-month period of 2023 amounted to $255 million, compared to $225 million in the current year, hence a cost decrease of approximately 12%. With this, we want to underscore that we are and will be very cost conscious and careful in how we prioritize our resources on our way to profitability. In 2026, we will continue focusing on our key markets: Germany, Spain, and Italy. And by that, we can move to the next slide, where we take a closer look at our operating expenses. Our research and development expenses decreased from an underlying 49 million in Q3 2023 to 22 million in this year's quarter. No clinical studies are currently ongoing within the phase three trial. Ocean was completed during the third quarter of 2023, and just as mentioned during that period, refunds of 43 million were received regarding final settlements for the completed study, which positively affected the cost. Corresponding refunds have not occurred during 2024. Hence, the underlying R&D cost is. Year to date, it is 34% below last year. If we look at our marketing and sales costs, they amounted to 30 million for this quarter, compared to 29 million last year. Behind the slightly increased cost are the ongoing commercialization activities in Europe, which Sofia will describe in more detail later in the presentation. Our administrative costs for the nine-month period amounted to 53 million, which is on par with last year's 53 million SEK. As the graph displays, we are actually decreasing costs this quarter compared to last year, which should be perceived as Oncopeptides building its organization with cost consciousness in a very effective way. We can now move to the next slide and have a look at our liquidity position. So by the end of the quarter, we had 250 million SEK in cash at hand. Of course, this was infused by the rights issue that was completed in May 2024. I also want to highlight that cash flow from operations in Q3 includes a negative timing effect of inflows and outflows and VAT payment of 105 million SEK, with a corresponding positive effect in the prior second quarter, meaning that the 250 million is really the true cash at the bank. And back to you, Sofia again.

Sofia Heigis
06:16 - 17:12

Thank you, Henrik. I will now talk a bit about the status of our European commercialization in general, followed by a deep dive into the dynamics, potential, and challenges of our three focus markets, with a particular focus on Germany. We expect that increasing our focus on Germany, Spain, and Italy will be enough to drive profitability by the end of 2026. The drivers of growth are that we have innovative pricing negotiated in Germany and Spain, and we do see encouraging progress in Italy according to our plans. We have also recently received national guideline updates in Germany and Spain. We observe an increased positive clinical experience. KOL advocacy, peer to peer exchange, and increased awareness. Advocacy, peer-to-peer exchange, and increased awareness. In Germany, we are already accessing 80% of healthcare regions, and in Spain, which is encouraging for sales pick-up in the second half of 2024 and the beginning of 2025. The graph displays our sales trajectory in revenue quarter over quarter, starting from the first quarter of 2023 up until the third quarter of 2024. We do see a clear positive growth trend, with variations informed by different factors across different quarters. In Q3, we did see strong growth in Spain, both in revenue and in sales. We did see a small increase in Germany in both revenue and sales. In fact, between Spain and Germany, we saw double-digit growth in sales, partly due to the decline in Greece. This was not fully translated into revenue, but still speaks to the growing demand in two of our key markets. Our European commercialization case is based on that. Oncopeptides has a fully approved drug for the treatment of an incurable disease, providing an expanding market opportunity valued at 1.5 billion SEK. Our focus right now is on growing sales in the markets where we have secured access, and on adding diversity to our revenue stream by unlocking new markets and finding partnerships for our geographic expansion. There are different steps in the market access process, and let me remind you of that. The timelines for the review and negotiation phases are country-specific and are, at large, controlled by payers. Since our quarterly update, we have progressed really well with Spain and we are now in the last phase of market access, which is to obtain regional access. And I said we have ensured access in record time. Approximately 80% of Spain. This has been achieved in such a short time, due to the high unmet need and the foundation of a positive clinical experience, generating demand for Pepaxti. I will speak even more about Spain in a little while. Italy has moved into the price negotiation phase and we are progressing according to our plan. Regarding the Netherlands, the payer environment is strict. There are intense discussions on how to get any new multiple myeloma drugs reimbursed. These restrictions will delay time to market for all drugs, and we have decided to put our efforts on hold until we see improved willingness to pay. This is unfortunate, but it is out of our control. We still see long-term potential in this market, but right now, we have decided to adjust our investment to the markets where we have access. We will have to carefully follow the development to make an informed decision on when to restart our efforts. Should we completely remove the market from our launch plan? We will, of course, clearly communicate that, and that is not the case here. We are strengthening our focus on the markets that we believe have the potential to make a true difference and bring us to profitability by the end of 2026. And I will now give an overview of these three markets with an emphasis on Germany. What is very apparent when you take a look at the three key markets for Oncopeptides next to each other, is the lack of clinical experience we had in Germany when launching Pepaxti. We are working hard to catch up. At the same time, the potential for a stronger sales pickup in markets where we have clinical experience is confirmed by the start in Spain. We, in addition, have had similar positive clinical experience pre-launch in Italy, from both key opinion leaders and early access programs and investigators, which we believe will support the launch from a prescriber perspective. Germany is the most scattered market, while Spain and Italy are more centralized. Regarding the size of the different target populations, Germany is the largest, followed by Italy, and then Spain. Now I wish to give you a better understanding of the dynamics. The critical success factors and opportunities in Germany. But first, if we boil it down to what really matters with a product like Pepaxti, I will repeat myself. It's all about generating a positive clinical experience that demonstrates the value of the drug. And we do have the opportunity, as we see physicians continue to prescribe Pepaxti. There are many patients who cannot tolerate or will not respond to immunotherapy and are in need of an option that provides a balance of clinically meaningful efficacy, tolerability, and quality of life. Looking at the different barriers, critical success factors, and opportunities in Germany. As said, we only had one key opinion leader with very limited clinical experience at launch in Germany. The critical success factor here is to ensure that key opinion leaders do get a positive clinical experience to be able to recommend and advocate for the drug. As of today, we have managed to get nine out of 17 key opinion leaders to gain a positive clinical experience. And I will show you a bit later what effect that can have on a territory. The first national guideline update since we launched has just occurred, and we know that we are included in the guidelines as the draft was recently presented and impacted, including our inclusion. This will, of course, also support the launch as all the medical education meetings are reviewing the guidelines. We had no clinical experience at launch among the prescribing physicians in hospitals or in office-based settings. In Germany, physicians commonly listen to their colleagues, and peer-to-peer exchange is critical to success. And as Pepaxti is a product that generates a positive clinical experience, peer-to-peer exchange is increasing in everyday practice. We have observed several local protocols and guidelines being updated, and we actively publish case reports to disseminate the experience generated. Germany is a very scattered market with many treating physicians, which makes it even more difficult to build clinical experience from the start of a launch. The key to success in such a market is, as I already mentioned, to gain KOL advocacy. This is a heat map of Germany, showing the population density of persons 65 years and older. That is the age of our patients. The bubbles in orange show the cumulative number of Pepaxti since launch until the end of the third quarter 2024 by ordering pharmacy location. As you can see, we are focusing on the most population-dense areas and in the regions where we generate clinical experience, and where we have key opinion leaders and key accounts, sales uptake is growing and accelerating. Regions began to generate experience in the second half of 2023, and these are now responsible for the majority of sales. We have also seen several regions start to gain experience in the second and third quarters of 2024, and we are expecting them to increase in the coming six months. Let's take a closer look at this. This graph shows five of the largest territories with the most dense population. And as you can see, there is a clear difference in regions one, two, and five. We have obtained sales and first prescriptions from Kohl's during 2023. And as you can see, it takes one to two quarters to see an acceleration in that territory. This is due to the positive clinical experience generated and the initiation of peer-to-peer exchange. The last couple of quarters, we have seen the first orders from key accounts in two other regions with great potential. And even if it's early days, we do believe that these territories will also be able to take off in the coming six months and support the acceleration of sales growth in Germany. The potential of Oncopeptides has not changed. While we are putting more effort into the first cycle of our core business, we have in no way forgotten about the next step. Value drivers. During the third quarter, we signed a partnership with SCBIO Inc. and we have received a first milestone payment, the first ever for Oncopeptides, and a testament to our ambition to build sales outside of Europe. We continue to entertain discussions with potential partners in both Japan and China. We also continue to progress our pipeline in a smart and efficient way, and we remain very confident in its potential to provide value to our shareholders and patients. As for next steps, we focus our efforts on PSP, the molecule announced in the last quarter. Moving towards IND submission. Meanwhile, we continue to evaluate the best way forward for our PDC molecule. And with that, I would like to say thank you to everyone listening and hand over to the moderator for any questions.

Operator
17:16 - 17:45

If you wish to ask a question, please dial pound five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound six on your telephone keypad. The next question comes from Richard Romanus from Redeye. Please go ahead.

Richard Romanus
17:48 - 18:02

Okay. Good morning. Thanks for taking my questions. Um, so starting with Germany, would you say that you have experienced good repeat orders from activated accounts?

Sofia Heigis
18:04 - 19:13

Thank you, Richard, and good morning. Uh, so looking at the third quarter in Germany, as we all know, it's a quarter of vacation period. And what we did see was that we did get repeat orders. We did not have many drop-out patients, but we also observed some delays and adjustments due to the holiday period. So, for example, some of the key accounts and key territories ordered with a longer interval between the different orders. And that is of course a benefit for patients and physicians with Pepaxti, in that if you have a response, you can look into adjusting treatments accordingly. Delay the treatment slightly and adjust it according to holidays and other factors. So, the short answer to your question is yes, we do see repeat orders. We continue to see a positive clinical experience. Um, and we also observed an impact on the frequency of repeat orders during this quarter due to the holiday period.

Richard Romanus
19:14 - 19:31

Okay. Um, you mentioned that Greece had a negative impact on sales. I thought that was quite a small market. Could you say something about how important Greece has been for the sales launch thus far?

Sofia Heigis
19:32 - 20:42

So when it comes to Greece, I would just like to remind you of the mechanisms we are selling there. In Greece, we're selling on an unnamed patient sales basis. And there is an authority called EFSA that is ordering. Commonly, they order more than one cycle of treatment. And what happened last quarter is that they used stock that they had stocked up for the patients in need of new treatments during this quarter. In regards to how important Greece is to our profitability goal and to our sales, we do not consider Greece to be a key market. I would like to emphasize that it's Germany, Spain, and Italy that are the markets we are focusing on with the greatest potential. Greece is a fairly small country with a population of 10 million. But the ordering pattern of them changed. And given that we are so early in the launch, of course, any decrease in orders will affect us.

Richard Romanus
20:44 - 21:11

Okay. Um, and, um. Considering your strategy to focus more on the three main markets, what does that mean for the other markets? Does that mean you will have less activities to gain access in the other countries? And will they be slightly delayed then?

Sofia Heigis
21:12 - 22:09

So when it comes to our launch phases, and if you recall, we have phase one, two, three, and four. The only market that we are putting on hold now is the Netherlands, due to the payer environment, because there is no way to get through there for us in the coming time. And hence, we would like to focus the investment on our key markets, where we do have the opportunity for access when it comes to smaller markets outside of Germany. And when I say Germany, I also include Austria, Spain, and Italy. We are continuing with market access activities, and we will, of course, ensure to have a focused and well-thought-out investment in those markets.

Richard Romanus
22:12 - 22:27

Okay. Um, my last question. Could you say anything more about when you think you can launch in Italy or any more details about progress with the market access there?

Sofia Heigis
22:28 - 22:51

So all I can share currently is that we have moved from the benefit assessment that was positive into the negotiation phase. And in regards to timelines, as I've already mentioned, this is controlled by the payers and I can't provide a specific timeline, but we do see encouraging progress.

Richard Romanus
22:53 - 22:54

Okay, great. Thank you so much.

Sofia Heigis
22:58 - 22:59

Thank you so much.

Operator
23:02 - 23:09

The next question comes from Suzanne van Voorthuizen from Van Lanschot Kempen. Please go ahead.

Unknown 1
23:12 - 23:32

Good morning. This is Van calling for Suzanne. Thank you for taking our questions. So my first question is about the lower than expected sales performance in Germany and Greece, particularly in Germany. Was it only impacted by the vacation period, or were there also other factors contributing to this?

Sofia Heigis
23:34 - 25:19

It was primarily our overview that we considered. So we buy sales data from our competitors. Overall, the market flattened out during the third quarter. And when we do our deep dive analysis, we can see that it's clear. As you can see on the map, we have identified certain territories where our growth is really accelerating. And when those territories had vacations, there was, as I also told Richard, more of a delay in ordering. Um, so we don't see any other factors than that. We are still early on with our launch efforts, as we are coming from a situation where we essentially had to start preparing the launch while we were already launching. And, we have, of course, been checking in with all our customers, ensuring that patients are doing well, and understanding the experience that we are generating to ensure that we don't miss anything in the market. The feedback is very positive from the experience perspective, and we don't see any other alarming dynamics. So it is really based on where we stand currently, how vulnerable we are to small changes during a quarter that is impacting this. And then I would like to emphasize that we did experience growth in Germany, albeit modest compared to, for example, Spain, but there was still growth. So it is really the decline in Greece that is causing our overall revenue to decrease.

Unknown 1
25:21 - 25:34

Okay. That is clear. And then I also wanted to know about the factors that caused the lower than expected sales. Do you think that these are also risks in other markets like Italy and Spain?

Unknown 2
25:38 - 25:39

Um, well.

Sofia Heigis
25:41 - 27:26

Italy and Spain are very different from Germany. Uh, and the strategy for markets, in terms of how scattered they are versus centralized, is important. Spain and Italy are more centralized. And there is also a difference in access as you go for national access at first, and then you need to negotiate or unlock your regional access in both Spain and Italy. It's difficult to compare the three markets in terms of launch uptake because Germany has been primarily affected by the inability to prepare for the launch adequately, given our starting point. Spain and Italy have been in the pre-launch phase for a longer duration as we need to unlock regional access. And that is a very decentralized process where different regions are unlocked at different time points. That's also why I'm emphasizing that we have had a national price for quite a short time in Spain, and yet we managed to unlock 80% of the regional access in Spain, which is very promising for the future. Because, looking at the drivers of sales, it is really a product that is giving a positive experience to both patients and physicians. Of course, for the right target patients. And that is really supporting us in Spain because we had that experience from before. So the physicians know how to use the drug. We do foresee that this will be the case in Italy as well, based on the vast experience from both clinical trials and early access programs.

Unknown 3
27:29 - 27:30

Okay.

Unknown 1
27:30 - 27:39

Thank you. And then my last question is about the preclinical programs. So, what are the next steps, and when will you disclose further data?

Sofia Heigis
27:40 - 28:28

Yes. So we have two platforms. We have the SPiKE immunotherapy platform. And as I mentioned, we have our first candidate drug, Op1. So, we are progressing one candidate into preclinical stages towards IND, conducting CMC work. As one example of those activities. We have still not secured financing for the clinical program when it comes to the clinical data and program. And we will, of course, work on that to be able to share when you will receive more clinical data. Um. Yeah. During the coming time, basically.

Unknown 1
28:30 - 28:32

Okay. Thank you.

Sofia Heigis
28:36 - 28:38

Thank you so much.

Operator
28:41 - 28:47

The next question comes from Yuri Serov from NA. Please go ahead.

Yuri Serov
28:49 - 29:19

Hi. Um. Morning question. Some very famous global opinion leaders continue promoting Melflufen Pepaxto at various conferences. But Oncopeptides seems to be incapable of growing sales at the pace that one might expect. Can now be the time to consider seeking a different owner for the program? Who can realize the full potential. Thank you.

Sofia Heigis
29:20 - 30:46

So you're right that we do have global key opinion leaders (KOLs) supporting us. That is again, based on their experience in the clinical development program. The reason we have difficulties delivering on market expectations from a German perspective is that we lacked local endorsement. And Germany is a market largely driven by the local KOLs, as most of the prescribers are out in the office-based setting. So from that perspective, we do not see a difference between us or if another company were to take on Pepaxti, because the same job has to be done. It is about unlocking advocacy by generating positive clinical experience. We also have a team that is covering all of Germany, and we have recruited team members from various companies with good networks within this community. We are confident in our model because we can see that it works, as I showed you on the graph. And then we as a company will, of course, always continue to assess how we can optimize and how we can accelerate.

Yuri Serov
30:47 - 30:56

But surely a larger company with an established name and network would be able to do that job more quickly.

Sofia Heigis
30:57 - 31:53

So if we look at the market in Germany and analyze the sales data, there are much larger companies launching currently. So we have Pfizer launching and we have Menarini Stemline launching their product. And, we don't see a lot of difference in the pace of growth between us and them. So you are right, and I understand your reasoning and thinking. And of course, our responsibility is always to pressure test our model, but for us, it's very clear what we need. To do. And even though we are moving slower, we are moving in the right direction. And if we believe that another player. A player would be able to do it even better. When we look at comparisons to our competitors, we of course look into that opportunity because we are really here to ensure that Pepaxti reaches patients.

Unknown 3
31:54 - 31:54

Okay.

Yuri Serov
31:54 - 31:55

Thank you.

Operator
32:08 - 32:16

There are no more phone questions at this time, so I hand the conference back to the speakers for any written questions and closing comments.

David
32:17 - 32:29

Yeah, there's one, David here ahead of, uh, there's one written question and I think you addressed it already, Sophia. But let's repeat, when can we expect the company to enter phase one with the SPiKE?

Sofia Heigis
32:31 - 32:56

So as I said, we are advancing in the pre-clinical phase and are undertaking activities to move towards IND preparedness. We are looking into different options on how to finance the clinical trials, hence phase one for the SPiKE program, and we will have to get back on timelines when we have decided in which direction we are moving.

David
32:57 - 33:02

That's all the written questions. So back to you, Sofia. Closing remarks.

Sofia Heigis
33:02 - 33:26

So thank you, everyone, for listening in today. And thank you so much for all the questions. I appreciate that you asked questions and that we have the opportunity to clarify. And as always, we are here to respond if there are further questions. Uh, any uncertainties. And by that, I would like to say thank you and wish you a good day.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…